Analytical methods
Genomic sequencing of coding exons and flanking intronic sequences.
Analytical validation
Confirmation of mutation in an independent biological sample of the index case and/or in an affected subject; segregation analysis in the parents of the index patient.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) 1:30 000-1:50 000. 1 1.9 If applicable, prevalence in the ethnic group of investigated person Unknown.
Diagnostic setting
Yes No
As penetrance is 100% and as disease is present from birth, the test is not used for predictive testing. 
TEST CHARACTERISTICS
Negative predictive value: It is 75-90% (refs 2-4) depending on the population-there is evidence for further genetic heterogeneity.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Above 95%.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
Although clinical expression can vary (complete and incomplete achromatopsia, rarely cone dystrophy and macular degeneration), clinical expression is expected to be 100% penetrant.
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: Although mutations in CNGA3, CNGB3, GNAT2, PDE6C and PDE6H are responsible for the majority of ACHM cases, further genetic heterogeneity is expected. Yet as achromatopsia is a congenital disorder, disease is evident early.
Index case in that family had not been tested: This approach cannot be supported. There is no specific therapy available, although gene therapy in relevant models is progressing.
CLINICAL UTILITY

Prognosis (please describe)
The genetic diagnosis essentially contributes to the classification of cases with similar clinical features. This is the basis for prognostic statements. Achromatopsia is expected to be a stationary disease, yet in rare cases progression and macular degeneration have been If the test result is negative (please describe): this will lead to reconsideration of the clinical diagnosis. The diagnosis of achromatopsia will therefore be either confirmed, suggesting a rare genetic form (genetic heterogeneity) for which the causative gene remains unknown, or invalidated and re-directed to, for example, blue cone monochromacy. 
